Published in Circulation on September 07, 1999
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (2013) 3.98
Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ (2005) 2.57
Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev (2011) 1.49
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol (2008) 1.34
Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes (2014) 1.19
Diabetic cardiomyopathy. Clin Sci (Lond) (2009) 1.18
Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev (2002) 1.16
Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy. Heart (2000) 1.13
Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC Heart Fail (2014) 1.06
The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci (2011) 1.03
Accuracy of noninvasive ejection fraction measurement in a large community-based clinic. Clin Med Res (2005) 0.97
Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One (2010) 0.95
Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br J Pharmacol (2000) 0.93
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag (2009) 0.90
Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia. Br J Pharmacol (2002) 0.90
Prognostic value of the six-minute walk test in heart failure patients undergoing cardiac surgery: a literature review. Rehabil Res Pract (2013) 0.88
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag (2010) 0.87
Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev (2007) 0.85
Angiotensin II blockade and renal protection. Curr Pharm Des (2013) 0.85
Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther (2010) 0.84
Changes in heart failure medications in patients hospitalised and discharged. BMC Fam Pract (2006) 0.83
Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly. Heart Fail Rev (2008) 0.83
Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension. Int J Hypertens (2012) 0.82
Lower rotation speed stimulates sympathetic activation during continuous-flow left ventricular assist device treatment. J Artif Organs (2014) 0.82
Preoperative beta-blocker treatment is a key for deciding left ventricular assist device implantation strategy as a bridge to recovery. J Artif Organs (2013) 0.81
[Drug treatment of chronic heart failure]. Clin Res Cardiol (2006) 0.80
Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure? Heart Fail Rev (2015) 0.80
Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan. Clin Exp Hypertens (2010) 0.80
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail (2008) 0.80
Valsartan in the treatment of heart attack survivors. Vasc Health Risk Manag (2006) 0.80
Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart (2001) 0.80
Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure. Br J Pharmacol (2001) 0.80
No HOPE without proof: do ARBs meet the standard for cardiovascular protection? Medscape J Med (2008) 0.79
Future pharmacologic agents for treatment of heart failure in children. Pediatr Cardiol (2006) 0.78
A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. Cardiovasc J Afr (2008) 0.78
Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Res Notes (2013) 0.78
Intratubular Renin-Angiotensin System in Hypertension. Curr Hypertens Rev (2006) 0.78
Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag (2009) 0.77
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging (2010) 0.77
Prevalence and prognostic significance of adrenergic escape during chronic beta-blocker therapy in chronic heart failure. Eur J Heart Fail (2009) 0.77
Aldosterone antagonism in heart failure. Vasc Health Risk Manag (2007) 0.77
Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice. Clin Res Cardiol (2009) 0.77
Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol (2003) 0.77
The autocrine/paracrine loop after myocardial stretch: mineralocorticoid receptor activation. Curr Cardiol Rev (2013) 0.77
ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease. Open Access Emerg Med (2010) 0.77
Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker. Heart Vessels (2011) 0.77
Heart failure management: the present and the future. Antioxid Redox Signal (2009) 0.77
More about the "ARB MI paradox". Heart (2007) 0.76
Are we ready to use aliskiren in children? Pediatr Nephrol (2010) 0.76
Role of angiotensin receptor blockers in heart failure: not yet RESOLVD. Circulation (1999) 0.76
Cheyne-stokes respiration and prognosis in modern-treated congestive heart failure. Lung (2009) 0.76
Aliskiren suppresses atrial electrical and structural remodeling in a canine model of atrial fibrillation. Heart Vessels (2016) 0.76
Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. Patient Relat Outcome Meas (2011) 0.75
Hypertensive therapy: attacking the renin-angiotensin system. West J Med (2001) 0.75
The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? Am J Cardiovasc Drugs (2016) 0.75
Effects of AT1 receptor antagonist therapy in patients with severe heart failure pretreated with angiotensin-converting enzyme inhibitors. Exp Clin Cardiol (2002) 0.75
Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases. Pediatr Nephrol (2013) 0.75
Candesartan in heart failure. Clin Interv Aging (2006) 0.75
Cardiac and vascular protection: the potential of ONTARGET. Medscape J Med (2008) 0.75
Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination at an urban medical center. MedGenMed (2007) 0.75
Effects of oral fixed-dose combinations of telmisartan plus ramipril and losartan plus ramipril in hypertension: A multicenter, prospective, randomized, double-blind, phase iii trial in adult indian patients. Curr Ther Res Clin Exp (2005) 0.75
Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors. CMAJ (2011) 0.75
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists. ACS Med Chem Lett (2015) 0.75
Angiotensin receptor blockers in heart failure after the ELITE II trial. Curr Control Trials Cardiovasc Med (2000) 0.75
The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials. J Clin Med Res (2016) 0.75
Protective effects of saponin on a hypertension target organ in spontaneously hypertensive rats. Exp Ther Med (2012) 0.75
AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment. Heart (2000) 0.75
Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System. Hypertension (2016) 0.75
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction. Integr Blood Press Control (2010) 0.75
Clinical trial update: focus on the ONTARGET study. Vasc Health Risk Manag (2007) 0.75
Effect of cardiac pacing on sleep-related breathing disorders: a systematic review. Heart Fail Rev (2016) 0.75
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord (2017) 0.75
Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients. Heart Vessels (2016) 0.75
Is cardiopulmonary exercise testing essential to indicate ventricular assist device implantation in patients with INTERMACS profile 4-7? J Artif Organs (2016) 0.75
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res (2005) 12.94
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med (2001) 8.74
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
The Newcastle exercise project: a randomised controlled trial of methods to promote physical activity in primary care. BMJ (1999) 8.16
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet (2000) 8.01
A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med (1995) 7.88
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
Emerging epidemic of cardiovascular disease in developing countries. Circulation (1998) 6.41
Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ (1999) 6.40
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science (1997) 6.10
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA (1991) 6.05
Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell (1987) 5.87
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81
Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med (2000) 5.41
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Use of a journal club and letter-writing exercise to teach critical appraisal to medical undergraduates. Med Educ (2001) 5.19
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
A combined PET/CT scanner for clinical oncology. J Nucl Med (2000) 4.99
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Neuraxial block, death and serious cardiovascular morbidity in the POISE trial. Br J Anaesth (2013) 4.60
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45
A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen Toxoplasma gondii. Science (2006) 4.44
Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth (1991) 4.40
Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet (1996) 4.28
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Hemophilus Hemolyticus Endocarditis. Am J Pathol (1933) 4.12
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut (2004) 4.06
Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA (1993) 4.01
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet (1998) 3.79
Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet (2002) 3.77
Babies sleeping with parents: case-control study of factors influencing the risk of the sudden infant death syndrome. CESDI SUDI research group. BMJ (1999) 3.76
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 3.72
Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J (1996) 3.66
Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med (1999) 3.63
Improving the repeat prescribing process in a busy general practice. A study using continuous quality improvement methodology. Qual Health Care (1999) 3.61
Epidemiology and causation of coronary heart disease and stroke in India. Heart (2008) 3.60
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J (2002) 3.56
Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology (2001) 3.52
Health and peace: time for a new discipline. Lancet (2001) 3.52
What do we know about how to do audit and feedback? Pitfalls in applying evidence from a systematic review. BMC Health Serv Res (2005) 3.51
The Uterine Mucosa in Menstruation and Pregnancy; the Action of the Chorionic Cells and the Function of the Decidua: Structure of the Uterine Mucosa and the Cause of the Opening-up of the Vessels during Menstruation. Proc R Soc Med (1911) 3.46
Ramipril and the development of diabetes. JAMA (2001) 3.38
Adenocarcinoma of colon differentiating as dome epithelium of gut-associated lymphoid tissue. Histopathology (2000) 3.36
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ (1999) 3.18
The AEtiology of Eclampsia and Albuminuria and their Relation to Accidental Haemorrhage: (An Anatomical and Experimental Investigation.). Proc R Soc Med (1914) 3.13
Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation (2000) 3.12
Morphology of sporadic colorectal cancer with DNA replication errors. Gut (1998) 3.11
Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med (1991) 3.08
Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol (2001) 3.07
Health promotion priorities for general practice: constructing and using "indicative prevalences". BMJ (1994) 3.04
Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics (2001) 3.02
Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest (1981) 2.97
Incidence and consequences of falls due to stroke: a systematic inquiry. BMJ (1995) 2.94
Why don't stage-based activity promotion interventions work? Health Educ Res (2004) 2.91
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ (1996) 2.90
Prevalence of coronary artery disease in Asian Indians. Am J Cardiol (1992) 2.90
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost (2011) 2.87
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation (1994) 2.84
Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ (1991) 2.81
DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? J Clin Pathol (1999) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation (2007) 2.76
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet (2000) 2.74
Prospective study of outcome in antenatally diagnosed renal pelvis dilatation. Arch Dis Child Fetal Neonatal Ed (1999) 2.73
Cross-hybridization of the chromosome 13/21 alpha satellite DNA probe to chromosome 22 in the prenatal screening of common chromosomal aneuploidies by FISH. Prenat Diagn (1995) 2.71
The scope and safety of short-stay surgery in the treatment of groin herniae and varicose veins. A report on 705 cases. Br J Surg (1972) 2.69
Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br J Clin Pharmacol (1978) 2.68
A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med (1997) 2.66